LUMOS PHARMA, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenues
Licensing and collaboration revenue
Royalty revenue
Total revenues
Revenues
Grant
Total revenues

Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income and expense:
Other income, net
Interest income
Interest expense

Other income, net
Net loss before taxes
Income tax benefit
Net loss
Accretion of preferred stock to current redemption value
Net loss attributable to common shareholders
Net loss per share:
Basic and diluted (in dollars per share)
Basic and diluted (in shares)
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted average number of common shares outstanding
Basic (in shares)
Diluted (in shares)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments
Total comprehensive loss

Comments